| |
THE USE OF omega 3 fatty acids in chronic kidney disease (CKD) patients has received a great deal of attention. Possible therapeutic applications include cardiovascular disease, uremia pruritus, erythropoietin resistance, hypertriglyceridemia, vascular access graft thrombosis, depressed albumin levels, and delaying the progression of CKD in certain diseases such as immunoglobulin A (IgA) nephropathy and lupus nephritis.1, 2, 3, 4, 5, 6, 7
The best source of omega 3 fatty acids remains debatable, but most literature supports the use of omega 3 fatty acids that have been metabolized to their final end product: docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).3, 8 EPA and DHA seem to reduce inflammatory activity by displacing arachidonic acid, which is the major precursor for proinflammatory processes. These inflammatory processes are thought to contribute to such conditions as hypoalbuminuria, pruritus, erythropoietin resistance, IgA nephropathy, and lupus nephritis.6
Other mechanisms of action include that omega 3 fatty acids are incorporated into the bilayer of cells, resulting in different membrane characteristics. These alterations may result in altered cell signaling, such as decreased platelet aggregation. This could explain the reason for improved graft patency and decreased cardiac events seen in studies using omega 3 fatty acids.3
Sources of Omega 3 Fatty Acids  Food preferences and product tolerances will determine what sources are best for your CKD patient. There are two different ways to obtain omega 3 fatty acids from food. One can consume foods high in EPA and DHA, or consume foods high in alpha linolenic acid (ALA), which then needs to be converted to EPA and DHA (done through an elongation process). One can also use omega 3 fatty acids supplements in their final elongated form of EPA and DHA. Other literature suggests that a combination of sources may be the most effective for the overall health benefits of omega 3 fatty acids in CKD.9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
Food Sources of Omega 3 Fatty Acids  Foods sources of omega 3 fatty acids can achieve some or all of patient needs for these fatty acids (Table 1). However, it may be difficult to meet this requirement to achieve some of the therapeutic benefits as shown below. ALA is the major omega 3 fatty acid in the human diet. However, the desaturation and elongation enzymes that convert ALA to EPA and DHA can vary from less than 0.1% into DHA and 15% into EPA.4, 9, 10, 11 DHA seems to be the most limiting in this conversion and may be one reason more preformed DHA will be important in therapeutic treatment.9, 10, 11 The desaturation and elongation enzymes that convert ALA acid to EPA also convert linoleic acid (LA) to arachidonic acid. Although ALA is the preferred substrate for this pathway, only small amounts of ALA are converted to EPA, probably because of the high ratio of LA:ALA present in cells. This is suggested as a reflection of the high ratio of LA:ALA observed in our Western diets. The ideal ratio of ALA to LA is 4:1; the typical American diet is estimated at 20:1.15, 17 | | |  | | Portion | Omega 3 g | Calories | Protein (g) | NA (mg) | K+ (mg) | P04 (mg) |  |
 | Plant sources | | | | | | | |  |
 | Flaxseed oil (linseed oil) | 1 tablespoon | 7.1 | 120 | 0 | 0 | 0 | 0 |  |
 | Canola oil (rapeseed oil) | 1 tablespoon | 1.6 | 124 | 0 | 0 | 0 | 0 |  |
 | Sunflower or safflower oil | 1 tablespoon | 0.2 | 120 | 0 | 0 | 0 | 0 |  |
 | Coconut oil | 1 tablespoon | 0.8 | 117 | 0 | 0 | 0 | 0 |  |
 | Wheat germ oil | 1 tablespoon | 1.0 | 120 | 0 | 0 | 0 | 0 |  |
 | Egg with enhanced omega 3 fatty acids⁎ | 50 g | 0.56 | 60–75 | 6 | 60–65 | 60–165 | 60–80 |  |
 | Soybeans, roasted⁎ | 3 oz | 1.5 | 387–499 | 30–34 | 2–140 | 1,264–1,173 | 312–558 |  |
 | Walnuts, english | 3 oz | 6.8 | 555 | 13 | 3 | 375–580 | 194 |  |
 | Walnuts, black | 3 oz | 3.3 | 525 | 20 | 3 | 444 | 435 |  |
 | Spinach-raw chopped | 1 cup | .39 | 7 | <1 | 24 | 167 | 15 |  |
 | Broccoli-raw | 1 cup | .097 | 25 | 3 | 25 | 287 | 58 |  |
 | Animal sources | | | | | | | |  |
 | Tuna, raw⁎ | 3 oz | 0.24–1.28 | 118–120 | 20–25 | 33–40 | 214–484 | 208–216 |  |
 | Tuna, light canned, drained, in oil | 3 oz | 0.26 | 168 | 25 | 301 | 176 | 264 |  |
 | Tuna, white, canned in water, drained | 3 oz | 0.73 | 109 | 20 | 320 | 201 | 184 |  |
 | Salmon, pink, canned | 3 oz | 1.48 | 90 | 15 | 420 | 173 | 141 |  |
 | Salmon, chinook, raw | 3 oz | 1.48 | 153 | 16 | 40 | 335 | 246 |  |
 | Salmon, Atlantic wild, raw | 3 oz | 0.9–1.56 | 121 | 17 | 37 | 417 | 170 |  |
 | Salmon, Atlantic farmed, raw | 3 oz | 1.09–1.83 | 156 | 16 | 50 | 308 | 198 |  |
 | Halibut, raw⁎ | 3 oz | 0.4–1.0 | 75–120 | 18–21 | 48–58 | 353–383 | 189–242 |  | | | |
|
⁎
More than one product was evaluated to determine this range of values. |
Patients should be counseled on avoiding over consumption of LA to optimize elongation from food high in ALA. The LA will compete for the same elongase and desaturase enzymes, interfering with omega 3 fatty acids metabolism to DHA and EPA from ALA.4 The literature is unclear regarding whether this elongation process is as efficient in diabetes mellitus and certain dermatological conditions, potentially because of a lack of the necessary enzyme (catalyst) for making this conversion. Other variables possibly impacting this conversation are trans fats, age, and gender. For people choosing to take ALA versus preformed EPA and DHA, consuming oils high in gamma linolenic acid (GLA) may help in this rate-limiting step delta 6-desaturase (D6D), such as black current oil, evening primrose oil, or borage oil. Vitamin B6 may also help in this conversion process.14, 19, 20, 21
Dosing Recommendations  The recommended oral dose of omega 3 fatty acids depends on the indication. The following doses are recommended1, 3:
•1 to 2 g/day to lower triglycerides
•4 g/day to lower blood pressure
•4 to 6 g/day to prevent thrombosis after placement of a hemodialysis graft
•6 g/day for treatment of uremic pruritus
•1 to 8 g EPA and 1.2 g DHA for IgA nephropathy
Supplements of Omega 3  For many patients, taking a supplement of omega 3 will be easier given the higher dose they may require. Table 2 is a list of recommended products based on current literature and resources available. These products were based on contents that seem acceptable to CKD patients and are more concentrated in content (to avoid the necessity of excess pill volume). | | |  | Product | Manufacturer City and State Contact Number | Contents |  |
 | Advocare Omegaplex Advocare International www.advocare.com | Carrollton, TX 972-478-4500 | Per soft gel: 300 mg EPA and 200 mg DHA |  |
 | Coromega Erbl, Inc. www.coromega.com | Vista, CA 877-275-3725 | Per packet: 20 calories, 350 mg EPA, 230 mg DHA, 70 mg other omega 3s, 25 mg vitamin C, 3 IU vitamin E, 50 μg folic acid. |  |
 | | | Other ingredients: egg yolk, 5 mg stevia leaf extract (sweetener), natural orange flavor, and vanillin |  |
 | Kirkland Signature Natural Fish Oil Concentrate Costco Wholesale Corporation www.costco.com | Issaquah, WA 800-774-2678 | Per soft gel: 150 mg EPA, 100 mg DHA |  |
 | Vitamin World Naturally Inspired Super DHA Natural Fish Oil Vitamin World www.vitaminworld.com | Bohemia, NY 888-645-7135 | Per soft gel: 10 calories, 300 mg EPA, 200 mg DHA. |  |
 | Other ingredients: gelatin and glycerin |  |
 | Carlson Super Omega 3 Fish Oils www.carlsonlab.com | Arlington Heights, IL 847-255-1600 | Per soft gel: 10 calories, 300 mg EPA, 200 mg DHA, 10 IU vitamin E (d-alpha). |  |
 | | | Other ingredients: beef gelatin, glycerin, water |  |
 | Omega-3 700 Solgar Vitamin and Herb www.Solgar.com | Leonia, NJ 877-SOLGAR-4 | Per soft gel: 15 calories. 360 mg EPA, 240 mg DHA, 100 mg other omega-3s, 4 IU vitamin E. |  |
 | | Other ingredients: caramel |  |
 | Omacor www.omacorrx.com | Reliant Pharmaceuticals 877-311-7515 | Per capsule: 465 mg EPA, 375 mg DHA, 60 mg DPA (docosapentaenoic acid) |  | | | |
For CKD patients, it is best to avoid products with added vitamin A and D, most likely derived from halibut or shark oils. Fish oil supplements that contain some vitamin E have been recommended to prevent rancidity.1, 4 In addition to EPA and DHA, some products contain mixed oil supplements. These additions are often expensive and unnecessary. Products that contain mainly EPA and DHA should be recommended.
Risks  Until recently, risks associated with omega 3 fatty acid supplements seemed minimal. Some concerns pertain to excessive intake on immune function and potentially increased risk of excessive bleeding and hemorrhagic stroke. An intake of <2 g/day is unlikely to cause this bleeding.4 A recent study suggested that patients with pacemakers might be at a slightly higher risk for arrhythmias with omega 3 supplements.18 If one is taking anticoagulation agents, in addition to omega 3 supplements, it has been suggested to routinely check prothrombin times (PT), in addition to careful monitoring of unusual bruising.1
References  1.
1
Burrowes J
, VanHouten G
.
Use of alternative medicine by patients with stage 5 chronic kidney disease
.
Adv Chronic Kidney Dis
. 2005;12:312–325
.
Abstract | Full Text |
Full-Text PDF (194 KB)
|
CrossRef
2.
2
Fiedler R
, Mall M
, Mall C
, et al.
Short-term administration of omega-3 fatty acid in hemodialysis patients with balanced lipid metabolism
.
J Ren Nutr
. 2005;15:253–256
.
Abstract | Full Text |
Full-Text PDF (74 KB)
|
CrossRef
3.
3
Donadio J
.
Briefing Document on the Potential Benefits of Omega 3 Fatty Acids
. Rochester, MN: Mayo Nephrology Collaborative Group; 2003;
.
4.
4
Omega 3 fatty acids. Dietary Supplement Issue No. 15, Vol. 4, Number 2, March-April 2003
5.
5
Clark WF
, Parbtani A
.
Symposium on essential fatty acid deficiency and omega 3 unsaturated fat in glomerulonephritis
(basis and practice)
.
Am J Kidney Dis
. 1994;23:644–647
.
Abstract 6.
6
Nephrology Pharmacy Association
.
Role of fish oil in dialysis
.
Med Facts
. 2002;4:2
.
7.
7
Vergili-Nelson J
.
Benefits of fish oil supplementation for hemodialysis patients
.
J Am Diet Assoc
. 2003;103:1174–1177
.
Abstract | Full Text |
Full-Text PDF (154 KB)
|
CrossRef
8.
8
www.naturaldatabase.com. Accessed September 2005.
9.
9
Gerster H
.
Can adults adequately convert alpha linolenic acid to eicosapentaenoic acid and docosahexaenoic acid
.
Int J Vitamin Nutr Res
. 1998;68:159–173
.
10.
10
Mantzioaris E
, James M
, Gibson R
, Clelland L
.
Dietary substitution with an alpha-lipoic acid rich vegetable oil increases eicosapentaneoic acid concentration in the tissues
.
Am J Clin Nutr
. 1997;65(Suppl 5):1304–1309
.
11.
11
Brenna JT
.
Efficiency of conversion of alpha linolenic acid to long chain n-3 fatty acids in man
.
Curr Opin Nutr Metab Care
. 2002;5:127–132
.
12.
12
Burdge GC
, Calder PC
.
Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults
.
Reprod Nutr Dev
. 2005;45:587–597
.
13.
13
Williams CM
, Burdge G
.
Long-chain n-3 PUFA
(plant v. marine sources)
.
Proc Nutr Soc
. 2006;65:42–50
.
MEDLINE 14.
14
Messina V
, Mangels R
, Messina M
.
In:
The Dietitian’s Guide to Vegetarian Diets
. (ed 2). 2005;p. 85–98
.
15.
15
Patel G
.
Essential fats in walnuts are good for the heart and diabetes
.
J Am Diet Assoc
. 2005;105:1096–1097
.
Full Text |
Full-Text PDF (52 KB)
|
CrossRef
16.
16
DeLorgeril M
, Salen P
.
Use and misuse of dietary fatty acids for the prevention and treatment of coronary heart disease
.
Reprod Nutr Dev
. 2004;44:283–288
.
MEDLINE 17.
17
deLorgeril M
, Salen P
.
Alpha-linolenic acid and coronary heart disease
.
Nutr Metab Cardiovasc Dis
. 2004;14:162–169
.
Abstract |
Full-Text PDF (837 KB)
|
CrossRef
18.
18
Sinclar AJ
, Attar-Bashi NM
.
What is the role of alpha-linolenic acid for mammals?
.
Lipids
. 2002;37:1113–1123
.
MEDLINE |
CrossRef
19.
19
Bordoni A
, Hrelia S
, Lorenzini A
, et al.
Dual influence of aging and vitamin B-6 deficiency on delta-67-desaturation of essential fatty acids in rat liver microsome
.
Prostaglandins Leukot Essent Fatty Acids
. 1998;58:417–420
.
Abstract |
Full-Text PDF (418 KB)
|
CrossRef
20.
20
Oxholm A
, Oxholm P
, daCunhaBang F
, Horrobin DF
.
Abnormal essential fatty acid metabolism in Darier’s disease
.
Arch Dermatol
. 1990;126:1308–1311
.
21.
21
Raitt M
, Conneor W
, Morris C
, et al.
Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patient with implantable defibrillators
.
JAMA
. 2005;293:1308–1311
.
St. Joseph Dialysis Center, Gig Harbor, Washington. Address reprint requests to Joan Brookhyser, RD, CSR, CD, 4700 Pointe Fosdick Drive Northwest, Suite 101, Gig Harbor, WA 98335.
PII: S1051-2276(06)00083-5 doi:10.1053/j.jrn.2006.04.003 © 2006 National Kidney Foundation, Inc. Published by Elsevier Inc All rights reserved. | 
31 of 31
|
| |
|